The Dermatologist

Can nutrition help manage cardiovascular risks in Psoriatic Arthritis? ??? A 12-week study found omega-3-rich diets improved protective HDL subfractions, even in high-risk patients. Recognizing atherogenic LDL profiles could redefine care for PsA. ???? https://okt.to/St5ydD #PsoriaticArthritis #CardiovascularHealth #NutritionScience #Omega3 #LipidMetabolism #Rheumatology #SkinHealth #FallDermatologyWeek

?? A study found that a history of non-melanoma skin cancer (NMSC) and the rate of prior tumors are key predictors for future NMSC development. These factors should be considered when designing future clinical trials on NMSC prevention. https://okt.to/Otpx07 #NMSC #ClinicalTrials #SkinCancerPrevention #Dermatology

In a recent Clinical Insights feature for The Dermatologist, "Strategies for Managing Pediatric Atopic Dermatitis," Dr Lisa Swanson shares her effective methods for diagnosing and assessing atopic dermatitis (AD) in children, emphasizing personalized care. "The psychological impact of AD for kids and their families is huge," she said. "Because the adjustments have occurred so slowly over time, they do not even realize how bad they have it until they go on a medicine or a therapy that helps their child feel better and sleep better." Access here: https://okt.to/xDTWU5 #dermatology #PediatricDermatology

Think you know the science behind Alopecia Areata? ???? Test your knowledge with this quick quiz: ?? Which cells drive AA inflammation and hair loss? ?? How do JAK inhibitors target cytokines? ?? What supports immune privilege at the hair follicle? Take the challenge and show off your dermatology smarts! ??? https://okt.to/cfn6tl #AlopeciaAreata #ImmunologyQuiz #JAKInhibitors #HairLossScience #Dermatology #SkinHealth #MedicalEducation #FallDermatologyWeek

Exploring alternatives in dermatology! ?? At Fall Dermatology Week, Dr Peter Lio highlighted natural options like fish oil for psoriasis, tea tree oil & spearmint tea for acne, and garlic for warts. Integrating these with conventional care offers personalized solutions for better outcomes. ? https://okt.to/A1vPLC #Dermatology #AlternativeMedicine #PsoriasisCare #AcneTreatment #WartRemedies #SkinHealth #FallDermatologyWeek

Hope for Alopecia Areata! ?? New therapies like JAK inhibitors, including baricitinib and ritlecitinib, are transforming treatment for severe AA, offering significant hair regrowth. Early diagnosis and intervention are key to better outcomes. ??? Brett King https://okt.to/3k4LEp #AlopeciaAreata #JAKInhibitors #HairLossTreatment #Dermatology #FallDermatologyWeek

New hope for vitiligo! ?? JAK inhibitors like ruxolitinib and baricitinib are showing promise in restoring pigmentation. Early diagnosis and a multidisciplinary approach can transform care and improve lives. ??? https://okt.to/PuILCM #VitiligoAwareness #Dermatology #JAKInhibitors #SkinHealth #FallDermatologyWeek

Revolutionizing care for Psoriasis and Psoriatic Arthritis with IL inhibitors! ?? At Fall Dermatology Week, Dr Joseph F. Merola, M.D. MMSc explored how targeted biologics like IL-23 and IL-17 inhibitors are transforming outcomes for patients, tackling both skin and joint inflammation. Early diagnosis and appropriate treatment are key to improving quality of life and preventing long-term damage. Let’s close the gap in care! ??? https://okt.to/0wrpJW #Psoriasis #PsoriaticArthritis #ILInhibitors #DermatologyWeek #SkinHealth #JointHealth #BiologicTherapies #PsO #PsA #HealthcareInnovation #Dermatology #Rheumatology

?? Debunking rosacea myths at the AAD Innovation Academy! Persistent redness is a key sign, not just genetics. Early treatment can make a big difference. ?? New treatments like silica microencapsulated benzoyl peroxide and extended-release minocycline are changing the game for clearer skin! ??? https://okt.to/BgelUw #RosaceaAwareness #DermatologyInnovation #ClearSkinJourney #SkinHealth #RosaceaTreatment #Minocycline #Erythema #SkincareScience #PatientCare #HealthAndWellness

Game changer for Hidradenitis Suppurativa! ?? FDA approves UCB's BIMZELX? (bimekizumab-bkzx) HCP, the first dual IL-17A & IL-17F inhibitor for moderate-to-severe HS. Clinical trials show deep, sustained symptom improvement up to 48 weeks. A new era in HS care begins! ??? https://okt.to/VstNkn Alexa B. Kimball, MD, MPH #HidradenitisSuppurativa #FDAApproval #HS #Bimekizumab #Dermatology #ChronicDisease #SkinHealth #InnovationInCare